Introduction {#s1}
============

Intensive efforts are currently dedicated towards the development of cell replacement therapies using cell types derived from human pluripotent stem cells (hPSC). Human insulin-producing beta cells represent a paradigm for this type of objective. These cells have a major physiological function, regulating circulating glucose levels by producing and secreting insulin. In patients suffering from type one diabetes, these cells are destroyed by an autoimmune mechanism, and would thus need to be replaced ([@bib4]). Beta cell replacement holds immense promises for diabetic patients and current strategies have reached major milestones ([@bib39]; [@bib45]; [@bib43]). However, it is well accepted that a more detailed understanding of beta cell development in human is required to generate unlimited functional human beta cells ([@bib30]).

The adult pancreas is composed of acinar cells that excrete enzymes into the duodenum through a ductal tree, and of endocrine cells (approximately 1% of the total pancreatic cells) that are clustered together forming the islets of Langerhans. The endocrine cells secrete hormones such as insulin (beta cells), glucagon (alpha cells) somatostatin (delta cells), pancreatic polypeptide (gamma cells) and ghrelin (epsilon cells). The pancreas develops from the primitive gut tube that evaginates into a dorsal and a ventral anlage ([@bib40]; [@bib28]). Multipotent epithelial pancreatic progenitors co-expressing the transcription factors PDX1 and NKX6-1 ([@bib37]; [@bib11]) proliferate upon signals (such as FGF10) from the adjacent mesenchyme ([@bib5]) and subsequently differentiate into the acinar, ductal and endocrine lineages. Endocrine commitment is initially marked by the expression of a basic helix-loop-helix transcription factor, NEUROG3, and followed by the expression of the mature endocrine markers ([@bib20]; [@bib21]).

Due to the difficulties associated with procuring staged human fetal tissues and the limited tools for their analysis, few data on human development is available and the majority of knowledge on tissue development derives from animal models. This also applies to the pancreas ([@bib28]) where only a limited number of studies have been performed on human pancreatic development. Theses studies demonstrate similarities but also differences between rodent and human pancreatic development ([@bib48]; [@bib28]; [@bib36]).

Knowledge on human pancreatic development remains limited. More information exists concerning human hematopoietic cell differentiation thanks to the characterization and use of cell surface antigens that enabled to identify, quantify and purify hematopoietic stem cells and progenitors at different stages of their development ([@bib17]). By mirroring the hematopoietic field, we developed here an approach where cell surface markers are used to recapitulate the hierarchical sequence of human pancreatic development. Specifically, we characterized the expression levels of specific markers at different stages of human pancreatic development corresponding to 7 to 12 weeks of development (WD). First we purified human pancreatic epithelial cells by selecting cells positive for the transmembrane glycoprotein EPCAM and by excluding CD45^+^ hematopoietic and CD31^+^ endothelial cells. Next we segregated pancreatic epithelial cells into four populations based on the GP2 and CDH1 (ECAD) expression levels. We observed that the expression levels of GP2 and ECAD correlate with acinar, ductal and endocrine functions. By using the additional cell surface markers CD142 and SUSD2 we further refined endocrine cell differentiation. Finally, our development model also applies to the in vitro differentiation of hPSCs into pancreatic endocrine cells.

Taken together our work provides a novel approach to study human fetal pancreas development and bridges the path between in vivo and in vitro differentiation of human pancreatic endocrine cells.

Results {#s2}
=======

EPCAM expression is restricted to the epithelium in the human fetal pancreas {#s2-1}
----------------------------------------------------------------------------

We tested if EPCAM can be used to purify human fetal pancreatic epithelial fraction enriched in pancreatic progenitors. CD31 and CD45 were used to exclude endothelial and hematopoietic cells respectively. Using this combination of antibodies on human fetal pancreatic cells (9.7WD), we detected three distinct fractions: the CD45^+^/CD31^+^ fraction (the endothelial/hematopoietic cells), the CD45^-^CD31^-^EPCAM^-^ fraction, and the CD45^-^CD31^-^EPCAM^+^ fraction ([Figure 1A](#fig1){ref-type="fig"}). To unveil which fraction contained the pancreatic progenitors, we assayed the expression of PDX1 and NKX6-1. Immunohistochemistry analysis of human fetal pancreatic sections showed that EPCAM^+^ cells expressed PDX1 ([Figure 1B](#fig1){ref-type="fig"}). FACS analysis demonstrated that PDX1 and NKX6-1 were co-expressed in the CD45^-^CD31^-^EPCAM^+^ fraction ([Figure 1C--E](#fig1){ref-type="fig"}). RT-qPCR analysis on sorted fractions confirmed that *PDX1* and *NKX6-1* expressions were restricted to the CD45^-^CD31^-^EPCAM^+^ fraction ([Figure 1F](#fig1){ref-type="fig"}) whereas the CD45^-^CD31^-^EPCAM^-^ fraction did not express pancreatic markers and most likely represent the mesenchymal pancreatic fraction (later referred as population M) ([Figure 1A](#fig1){ref-type="fig"}). These results suggest that a combination of the cell surface markers EPCAM, CD45, and CD31 can be used to purify the human fetal pancreatic epithelial fraction.10.7554/eLife.27564.002Figure 1.EPCAM expression in the human fetal pancreas.(**A**) The flow cytometry plot represents CD45 and CD31 expression against EPCAM gated on live human fetal pancreatic cells (9.7WD), n = 9. (**B**) Immunohistochemistry for PDX1 and EPCAM on pancreatic section (9WD), n = 3. Scale bar = 100 μm. (**C--E**) Flow cytometry plots of PDX1 and NKX6-1 expression at 9.4WD on CD45^+^/CD31^+^ cells (red square), CD45^-^CD31^-^EPCAM^-^ cells (TN = triple negative green square) and CD45^-^CD31^-^EPCAM^+^ cells (blue square). (**F**) RT-qPCR analysis of *PDX1* and *NKX6-1* expression on sorted CD45^-^CD31^-^EPCAM^+^ and TN cells. ND = Not Detected.**DOI:** [http://dx.doi.org/10.7554/eLife.27564.002](10.7554/eLife.27564.002)

GP2 and ECAD define four populations in the human fetal pancreatic epithelium that develop sequentially {#s2-2}
-------------------------------------------------------------------------------------------------------

Recently, GP2 was identified as a novel cell surface marker of the immature pancreatic progenitor cells derived from hPSC ([@bib1]). Furthermore, additional data indicate that ECAD levels are tightly modulated during endocrine differentiation ([@bib19]). Therefore, we analyzed GP2 and ECAD expression levels in the CD45^-^CD31^-^EPCAM^+^ fraction at 9.4WD. GP2 expression in CD45^-^CD31^-^ was restricted to the EPCAM^+^ fraction ([Figure 2---figure supplement 1](#fig2s1){ref-type="fig"}). GP2 and ECAD expression segregated the CD45^-^CD31^-^EPCAM^+^ fraction into four distinct populations: GP2^hi^ECAD^+^ (named GP2^hi^), GP2^+^ECAD^+^ (named GP2^+^), GP2^-^ECAD^+^ (named GP2^-^), and the GP2^-^ECAD^low^ (named E^low^) ([Figure 2A](#fig2){ref-type="fig"}). Remarkably, the cell frequencies of the four populations were well conserved from one pancreas to the other, demonstrating inter-individual homogeneity ([Figure 2B](#fig2){ref-type="fig"}). We assayed the dynamic expression of GP2 and ECAD in the pancreatic epithelial fraction (CD45^-^CD31^-^EPCAM^+^) during development (from 7WD to 12WD) ([Figure 2C](#fig2){ref-type="fig"}). At 7WD the epithelial fraction was essentially GP2^+ ^(96 ± 1%). From 7WD to 8.4WD, the GP2^-^ population evolves from 2 ± 1% to 34 ± 6% (p\<0.05) ([Figure 2C,D](#fig2){ref-type="fig"}). Interestingly, from 8.6WD, we detected cells with a lower ECAD level ([Figure 2---figure supplement 2A,B](#fig2s2){ref-type="fig"}). This E^low^ population further increased in frequency from 10 ± 2% at 9.4WD to 18 ± 3% at 12WD (p\<0.05) ([Figure 2C,D](#fig2){ref-type="fig"}). At 9.4WD, we also detected a GP2^hi^ population, increasing in frequency during development (3 ± 1% at 9.4WD to 20 ± 5% at 12WD; p\<0.05) ([Figure 2C,D](#fig2){ref-type="fig"} and [Figure 2---figure supplement 2C](#fig2s2){ref-type="fig"}). Altogether, the temporal and continuum GP2 and ECAD expression suggest a progeny relationship between specific cell populations, the GP2^+^ population would differentiate either into a GP2^hi^ population or into a GP2^-^ population that would later decrease its ECAD level to give rise to the E^low^ population ([Figure 2E](#fig2){ref-type="fig"}).10.7554/eLife.27564.003Figure 2.GP2 and ECAD expression in the human fetal pancreatic epithelium.GP2 and ECAD expressions were assayed by flow cytometry during development. (**A**) FACS plots display the expression at 9.4WD of CD45 and CD31 against EPCAM (left plot) and GP2 and ECAD gated on CD45^-^CD31^-^EPCAM^+^ (right plot). n = 4 (**B**) Cell frequencies of the GP2^hi^ (GP2^hi^ECAD^+^), GP2^+^ (GP2^+^ECAD^+^), GP2^-^ (GP2^-^ECAD^+^) and E^low^ (GP2^-^ECAD^low^) populations at 9.4WD. n = 4 (mean ±SEM) (**C**) GP2 and ECAD expressions on fetal pancreases at 7-12WD gated on CD45^-^CD31^-^EPCAM^+^ cells. 7WD n = 2, 8.4WD n = 9, 9.4WD n = 4, 12WD n = 5. (mean ±SEM) (**D**) Cell frequencies of the GP2^hi^, GP2^+^, GP2^-^ and E^low^ populations at 7-12WD. Cell frequencies were calculated from three independent experiments for each time point. (**E**) Scheme that represents the development of GP2^hi^, GP2^+^, GP2^-^ and E^low^ populations.**DOI:** [http://dx.doi.org/10.7554/eLife.27564.003](10.7554/eLife.27564.003)10.7554/eLife.27564.004Figure 2---source data 1.Cell frequency at 9.4WD by flow cytometry.Cell frequencies of the GP2^hi^ (GP2^hi^ECAD^+^), GP2^+^ (GP2^+^ECAD^+^), GP2^-^ (GP2^-^ECAD^+^) and E^low^ (GP2^-^ECAD^low^) populations at 9.4WD. n = 4 (mean ± SEM). Cell frequencies were calculated from four independent experiments for each time point.**DOI:** [http://dx.doi.org/10.7554/eLife.27564.004](10.7554/eLife.27564.004)10.7554/eLife.27564.005Figure 2---source data 2.Cell frequency during development.Cell frequencies of the GP2^hi^, GP2^+^, GP2^-^ and E^low^ populations at 7-12WD. Cell frequencies were calculated from three independent experiments for each time point.**DOI:** [http://dx.doi.org/10.7554/eLife.27564.005](10.7554/eLife.27564.005)10.7554/eLife.27564.006Figure 2---figure supplement 1.Gating strategy for GP2 and ECAD.Human fetal pancreas at 9WD was stained for CD45, CD31, EPCAM, ECAD and GP2. Doublets cells were excluded from the analysis with FSC-H and FSC-W (middle top plot). Propidium iodide was used to exclude dead cells as shown in the right top plot in the diagonal. GP2 and ECAD expressions were analyzed in CD45^+^/CD31^+^ (red square), CD45^-^CD31^-^EPCAM^-^ (green square) and CD45^-^CD31^-^EPCAM^+^ (green square) compartments. CD45^-^CD31^-^EPCAM^-^ population was used as negative control to set up the GP2^-^ECAD^+^ (named GP2^-^) and GP2^+^ECAD^+^ (named GP2^+^) gates. GP2^+^ECAD^+^ population was used to set up the gate for ECAD levels. This experiment is representative of 5 independent stainings at 9WD. This gating strategy was applied to each pancreatic stage.**DOI:** [http://dx.doi.org/10.7554/eLife.27564.006](10.7554/eLife.27564.006)10.7554/eLife.27564.007Figure 2---figure supplement 2.Expression of ECAD and GP2 during development.(**A**) GP2 and ECAD expression by flow cytometry on CD45^-^CD45^-^EPCAM^+^ population at 8.4, 8.6 and 9.4WD. (**B**) ECAD expression in the GP2^+^ (in blue) and all GP2^-^ (GP2^-^ECAD^+^+GP2ECAD^low^, in red) populations at 8.4, 8.6 and 9.4WD. (**C**) GP2 expression by flow cytometry on CD45^-^CD31^-^EPCAM^+^ at 8.4, 10.6 and 13.1WD. GP2^hi^ gates were fixed at 13.1WD for the three stages. (**A, B**) 8.4WD n = 7, 8.6WD n = 7 and 9.4WD n = 3. (**C, D**) 8.4WD n = 7, 10.6WD n = 3, 13.1WD n = 2.**DOI:** [http://dx.doi.org/10.7554/eLife.27564.007](10.7554/eLife.27564.007)

Acinar and endocrine functions segregate within the GP2 and ECAD populations {#s2-3}
----------------------------------------------------------------------------

To characterize the four epithelial populations described above, we sorted the GP2^hi^, GP2^+^, GP2^-^ and E^low^ populations and performed global transcriptomic analyses combined with RT-qPCR analyses at 9 and 11WD. As a non-epithelial control, we included the CD45^-^CD31^-^EPCAM^-^ fraction (population M) ([Figure 1A](#fig1){ref-type="fig"}). Due to limitations in cell numbers, the GP2^hi^ population was only sorted at 11WD. Principal component analysis (PCA) on the sorted populations at 9WD revealed three clusters. PC1 separated the epithelial populations (GP2^hi^, GP2^+^, GP2^-^ and E^low^) from the mesenchymal fraction (M), while PC2 segregated the E^low^ population from the GP2^hi^, GP2^+^ and GP2^-^ populations ([Figure 3A](#fig3){ref-type="fig"}). Gene Set Enrichment Analysis (GSEA) using Gene Ontology database indicated that digestion was the most represented biological process in the GP2^hi^ and GP2^+^ populations while endocrine functions (insulin and peptide secretion, hormone secretion) were enriched in the E^low^ population ([Figure 3B](#fig3){ref-type="fig"}, [Figure 3---figure supplement 2](#fig3s2){ref-type="fig"}). Conversely the pancreatic functions appeared less enriched in the GP2^-^ population. Next, we defined the list of the 'specific enriched genes' per population ([Supplementary file 1b---c](#SD3-data){ref-type="supplementary-material"} and Materials and method section). We compared the fetal 'specific enriched genes' with the RNAseq Single Cell data from human adult pancreas ([@bib49]) ([Figure 3---figure supplement 3](#fig3s3){ref-type="fig"}). The GP2^hi^ population displayed 27 enriched genes (p\<0.05), 85% being preferentially expressed in the adult acinar cells ([Figure 3C](#fig3){ref-type="fig"}, and [Figure 3---figure supplement 3A](#fig3s3){ref-type="fig"}). In contrast, the E^low^ population contained 91 (at 9WD) and 34 (at 11WD) differentially expressed genes (p\<0.05) that were also enriched (98% and 100% respectively) in the adult endocrine cells (alpha, beta, delta, epsilon or gamma cells) ([Figure 3C](#fig3){ref-type="fig"}, and [Figure 3---figure supplement 3B](#fig3s3){ref-type="fig"}).10.7554/eLife.27564.008Figure 3.Transcriptomic analysis of the GP2^hi^, GP2^+^, GP2^-^ and E^low^ populations.(**A**) PCA map of sorted pancreatic cells (epithelium and mesenchyme). (**B**) Top enriched biological processes in each cell population compared to the mesenchyme. Results were obtained with GSEA software using the GO database. (**C**) PCA map of epithelial-sorted cells (GP2^hi^, GP2^+^, GP2^-^ and E^low^ populations) from 9 (top map) and 11WD (bottom map). The number of specifically genes enriched in each population in each population (p\<0.05) is displayed. PCA maps are displayed in 2D with the three Principal Components on figure [Figure 3---figure supplement 1](#fig3s1){ref-type="fig"}) and the Gene Ontology lists in [Supplementary file 1a](#SD3-data){ref-type="supplementary-material"}.**DOI:** [http://dx.doi.org/10.7554/eLife.27564.008](10.7554/eLife.27564.008)10.7554/eLife.27564.009Figure 3---figure supplement 1.Principal component analysis.(**A**) 2D PCA maps of sorted pancreatic cells (epithelium and mesenchyme) displaying the first three Principal Components (PC1 against PC2, PC1 against PC3 and PC2 against PC3) from [Figure 3A](#fig3){ref-type="fig"}. (**B**) 2D PCA maps of sorted epithelial cells (GP2^hi^, GP2^+^, GP2^-^ and E^low^ populations) at 9WD displaying the first three Principal Components (PC1 against PC2, PC1 against PC3 and PC2 against PC3) from [Figure 3C](#fig3){ref-type="fig"} (top map). (**C**) 2D PCA maps of sorted epithelial cells (GP2^hi^, GP2^+^, GP2^-^ and E^low^ populations) at 11WD displaying the first three Principal Components (PC1 against PC2, PC1 against PC3 and PC2 against PC3) from [Figure 3C](#fig3){ref-type="fig"} (top map) from [Figure 3C](#fig3){ref-type="fig"} (bottom map).**DOI:** [http://dx.doi.org/10.7554/eLife.27564.009](10.7554/eLife.27564.009)10.7554/eLife.27564.010Figure 3---figure supplement 2.Heatmaps of genes from GO Biological processes digestion, insulin secretion and pancreas development.Enriched genes from GO biological processes « digestion » (**A**), « insulin secretion » and «pancreas development» (**B**) were used to generate heatmaps. They display expression of these genes at 9 and 11WD in the GP2^hi^, GP2^+^, GP2^-^, E^low^ and Mesenchyme populations. Heatmaps were generated by the 'heatmap2' function from gplots R package on standardized log2 expression values, with Pearson correlation as the distance function.**DOI:** [http://dx.doi.org/10.7554/eLife.27564.010](10.7554/eLife.27564.010)10.7554/eLife.27564.011Figure 3---figure supplement 3.The GP2^hi^ and E^low^ populations are enriched in acinar and endocrine markers respectively.Comparative analyses using data from [@bib49] indicate that (**A**) Genes found enriched in the GP2^hi^ population, are preferentially expressed in the human adult pancreas in acinar cells (**B**) Genes found enriched in the E^low^ population, are preferentially expressed in the human adult pancreas in endocrine cells. Heatmaps were obtained with Log2 RPKM values of the 1000 characterized single cells from ([@bib49]).**DOI:** [http://dx.doi.org/10.7554/eLife.27564.011](10.7554/eLife.27564.011)

We next generated heatmaps based on Gene Ontology lists and selected acinar, ductal and endocrine genes. By RT-qPCR analyses we confirmed that acinar markers such as *CEL, CELA3A* and *CTRC* were enriched in the GP2^+^ population at 9WD and in the GP2^hi^ population at 11WD ([Figure 3---figure supplement 2A](#fig3s2){ref-type="fig"}, [Figure 4A](#fig4){ref-type="fig"}). Ductal markers (*CFTR, KRT19* and *SPP1*) were enriched in the GP2^+^ and GP2^-^ populations, especially *CFTR* at 9WD and 11-13WD ([Figure 4---figure supplement 1](#fig4s1){ref-type="fig"}). The E^low^ populations (9 and 11WD) were enriched with endocrine transcription factors such as *ARX, PAX4, PAX6, NEUROD1, MAFA, MAFB, ISL1* and *NKX2.2* and hormones like *CHGA, GCG, GHRL* and *INS* ([Figure 3---figure supplement 2B](#fig3s2){ref-type="fig"}, [Figure 4B](#fig4){ref-type="fig"}).10.7554/eLife.27564.012Figure 4.Characterization of the GP2^hi^, GP2^+^, GP2^-^ and E^low^ populations.(**A,B**) Expression of acinar (**A**) and endocrine (**B**) markers in the GP2^hi^, GP2^+^, GP2^-^ and E^low^ populations by global transcriptomic analyses and by RT-qPCR. (**C**) Expression of *NEUROG3* by RT-qPCR in the GP2^hi^, GP2^+^, GP2^-^ and M populations. Heat maps and RT-qPCR are representative of 3 independents experiments. ND = Non Detected. M = CD45^-^CD31^-^EPCAM^-^. \*p\<0.05, \*\*p\<0.001, *t* test. (mean ± SEM).**DOI:** [http://dx.doi.org/10.7554/eLife.27564.012](10.7554/eLife.27564.012)10.7554/eLife.27564.013Figure 4---figure supplement 1.Expression of ductal markers in the GP2^hi^, GP2^+^, GP2^-^ and E^low^ populations.Expression of ductal markers in the GP2^hi^, GP2^+^, GP2^-^ and E^low^ populations by transcriptomic analysis (**A**) and RT-qPCR (9-13WD) (**B**). ND = Not Detected. M = CD45CD31^-^EPCAM^-^. Heatmaps and RT-qPCR are representative of 3 independents experiments. (mean ± SEM).**DOI:** [http://dx.doi.org/10.7554/eLife.27564.013](10.7554/eLife.27564.013)

Finally, to define the cell population where endocrine cells first differentiate, we followed the expression of the endocrine progenitor marker *NEUROG3. NEUROG3* was first detected at 8.4WD in the GP2^-^ population ([Figure 4C](#fig4){ref-type="fig"}) prior to the detection of the E^low^ population ([Figure 2C](#fig2){ref-type="fig"}) and next (9 to 13WD), found enriched in the E^low^ population ([Figure 4C](#fig4){ref-type="fig"}). Thus, our data suggest that the first human pancreatic endocrine progenitors differentiate in the GP2^-^ population and mature while decreasing ECAD levels in the E^low^ population.

CD142 and SUSD2 reveal heterogeneity within the GP2^-^ and E^low^ populations during development {#s2-4}
------------------------------------------------------------------------------------------------

The GP2^-^ population displayed both duct and endocrine progenitor cells markers suggesting it contains more than one cell type. We therefore sought for additional discriminant markers by scrutinizing our transcriptomic data. We observed two cell surface markers, CD142 and SUSD2 with opposite expression patterns: the E^low^ population expressed lower *CD142* and higher *SUSD2* mRNA levels than the GP2^+^ and GP2^-^ populations ([Figure 5A](#fig5){ref-type="fig"}). FACS analyses showed that at 9.4WD, the GP2^hi^ and GP2^+^ populations were uniformly CD142^+^SUSD2^-^, while the GP2^-^ and E^low^ populations were further divided into three subsets: CD142^+^SUSD2^-^, CD142^-^SUSD2^-^ and CD142^-^SUSD2^+^ ([Figure 5B](#fig5){ref-type="fig"}). Noteworthy, the CD142^-^SUSD2^+^ subset was scarce in the GP2^-^ population (6%), but represented 40% of the E^low^ population at 9.4WD ([Figure 5B](#fig5){ref-type="fig"}). Accordingly, our data reflects the heterogeneity within the GP2^-^ and E^low^ populations that is further resolved using CD142 and SUSD2 antibodies.10.7554/eLife.27564.014Figure 5.Expression of CD142 and SUSD2 in the GP2^hi^, GP2^+^, GP2^-^ and E^low^ populations.(**A**) Expression of *CD142* and *SUSD2* in GP2^+^, GP2^-^ and E^low^ populations at 9WD by microarray analysis. Boxplots were obtained using standardized log2 expression values. (**B**) Expression of CD142 and SUSD2 in the GP2^hi^ (in green), GP2^+^ (in red), GP2^-^ (in purple) and E^low^ (in orange) populations at 9.4WD by flow cytometry. GP2 and ECAD expressions were gated on live CD45^-^CD31^-^EPCAM^+^ cells. (**C**) Expression of CD142 and SUSD2 in the GP2^+^ (left plot), GP2^-^ (right plot) and E^low^ (far right plot) populations at 7WD, 8.4WD, and 11.3WD. (**D**) Cell frequencies of the GP2^-^CD142^+^SUSD2^-^ (named CD142^+^SUSD2^-^ in yellow) and the GP2^-^CD142^-^SUSD2^-^ (CD142^-^SUSD2^-^ in red) subsets from 7WD to 9.4WD. (mean ± SEM). (**E**) Cell frequencies of the E^low^GP2^-^CD142^-^SUSD2^+^ (named E^low^SUSD2^+^, in purple) and the E^low^GP2^-^CD142^-^SUSD2^-^ (E^low^SUSD2^-^, in green) subsets from 7 to 12WD. (mean ± SEM). (**A**) n = 2--3, (**B**) n = 3; **C**) 7WD n = 2, 8.4WD to 9.4WD n = 3. (**D**) n = 3.**DOI:** [http://dx.doi.org/10.7554/eLife.27564.014](10.7554/eLife.27564.014)10.7554/eLife.27564.015Figure 5---figure supplement 1.Expression of CD142 and SUSD2 in the GP2^+^, GP2^-^ and E^low^ populations at 8.6WD.Expression of CD142 and SUSD2 in the GP2^+^ (in red), GP2^-^ (in purple) and E^low^ (in orange) populations at 8.6WD by flow cytometry. GP2 and ECAD expressions were gated on live CD45^-^CD31^-^EPCAM^+^ cells. n = 7.**DOI:** [http://dx.doi.org/10.7554/eLife.27564.015](10.7554/eLife.27564.015)

Next we examined the CD142 and SUSD2 expression patterns in the GP2^-^ and in the E^low^ populations during development. At 7WD the majority of the GP2^-^ population was CD142^+^SUSD2^- ^(95 ± 2%). This frequency gradually decreased to 62 ± 2% at 9.4WD while the frequency of the CD142^-^SUSD2^-^ subset increased from 5 ± 2% at 7WD to 43% at 11.3WD p\<0.05 ([Figure 5C,D](#fig5){ref-type="fig"}). We detected the first SUSD2^+^ cells in the GP2^-^CD142^-^ subset at a low frequency (1%) at 8.4WD ([Figure 5C](#fig5){ref-type="fig"}). The first E^low^ population was detected at 8.6WD and was divided into CD142^+^SUSD2^-^, CD142^-^SUSD2^-^ and CD142^-^SUSD2^+^ subsets ([Figure 2---figure supplement 2A,B](#fig2s2){ref-type="fig"} and [Figure 5---figure supplement 1](#fig5s1){ref-type="fig"}). As development progressed the frequency of the E^low^CD142^-^SUSD2^+^ subset decreased (from 48 ± 7% at 8.6WD to 10 ± 1% at 12WD; p\<0.05), while the frequency of the E^low^CD142^-^SUSD2^-^ subset increased (from 30 ± 4% at 8.6WD to 79 ± 3% at 12WD; p\<0.05) ([Figure 5B,C,E](#fig5){ref-type="fig"}). Our data thus indicate that the first GP2^-^ cells are CD142^+^. They progress in their differentiation program by down-regulating CD142, then up-regulating SUSD2 and finally decreasing ECAD levels.

Endocrine progenitors develop in the GP2^-^CD142^-^SUSD2^-^ subset and mature within the E^low^SUSD2^+^ subset {#s2-5}
--------------------------------------------------------------------------------------------------------------

We analyzed the expression pattern of endocrine markers from 8.6WD to 13WD in the three E^low^ subsets. The E^low^CD142^+^SUSD2^-^ subset did not express endocrine markers such as *CHGA* and *NEUROG3* ([Figure 6---figure supplement 1](#fig6s1){ref-type="fig"}). At 8.6WD, *CHGA*, *NEUROD1, NKX2-2* and *INS* were solely detected in the E^low^CD142^-^SUSD2^+^ subset ([Figure 6A](#fig6){ref-type="fig"}). Interestingly, at 10-12WD, *CHGA*, *NEUROD1* and *NKX2-2* expressions were detected both in the E^low^CD142^-^SUSD2^+^ and the E^low^CD142^-^SUSD2^-^ subsets while *INS* was exclusively detected in the E^low^CD142^-^SUSD2^-^ subset ([Figure 6B](#fig6){ref-type="fig"}).10.7554/eLife.27564.016Figure 6.Molecular characterization of the GP2^-^CD142^-^SUSD2^-^ and E^low^GP2^-^CD142^-^SUSD2^-^ subsets.(**A, B**) RT-qPCR for *CHGA, NEUROD1, NKX2-2* and *INS* on sorted GP2^-^CD142^+^SUSD2^-^ (GP2^-^CD142^+^), GP2^-^CD142^-^SUSD2^-^ (GP2^-^CD142^-^), E^low^GP2^-^CD142^-^SUSD2^+^ (E^low^SUSD2^+^) and E^low^GP2^-^CD142^-^SUSD2^-^ (E^low^SUSD2^-^) subsets at 8.6 and 10-12WD. (**C**) RT-qPCR for *NEUROG3* at 8.4, 8.6, 9 and 11-13WD in the GP2^-^CD142^+^SUSD2^-^ (GP2^-^CD142^+^), GP2^-^CD142^-^SUSD2^-^ (GP2^-^CD142^-^), E^low^GP2^-^CD142^-^SUSD2^+^ (E^low^SUSD2^+^) and E^low^GP2^-^CD142^-^SUSD2^-^ (E^low^SUSD2^-^) subsets. (**D, E**) Single cell RT-qPCR at 9WD on 172 GP2^-^CD142^+^SUSD2^-^ (GP2^-^SUSD2^-^, left panel) and 166 E^low^GP2^-^CD142^-^SUSD2^+^ (SUSD2^+^, right panel) cells for the expression of *PPIA*, *NEUROG3*, *NEUROD1*, *NKX2-2* and *CFTR*. Pie charts represent the percentage of *NEUROG3^+^* (in orange), *NEUROG3^-^CFTR^+^* (in blue) and *NEUROG3^-^CFTR^-^* cells (in grey). For *NEUROG3^+^* the percentages of *NEUROD1^+^*, *NKX2-2^+^*, and *CFTR^+^* cells are displayed. Each line represents one cell. *PPIA^-^* cells were excluded from the analysis. (**A--C**) n = 3, (**D, E**) n = 2. \*p\<0.05, \*\*\*\*p\<0.0001, *t* test. (mean ±SEM).**DOI:** [http://dx.doi.org/10.7554/eLife.27564.016](10.7554/eLife.27564.016)10.7554/eLife.27564.017Figure 6---figure supplement 1.Expression of *CHGA* and *NEUROG3* in the E^low^CD142^+^ subsets.RT-qPCR for *CHGA* and *NEUROG3* in the GP2^-^CD142^+^SUSD2^-^ (named GP2^-^CD142^+^), E^low^CD142^+^, E^low^GP2^-^CD142^-^SUSD2^+^ (named E^low^SUSD2^+^) and M (CD45^-^CD45^-^EPCAM^-^) populations. Heatmaps and RT-qPCR are representative of 3 independents experiments. (mean ± SEM).**DOI:** [http://dx.doi.org/10.7554/eLife.27564.017](10.7554/eLife.27564.017)

Next we assessed *NEUROG3* expression in the different subsets. The first *NEUROG3^+^* were detected in the GP2^-^CD142^-^ subset at 8.4WD before SUSD2 up-regulation ([Figure 6C](#fig6){ref-type="fig"}). From 8.6WD, when the E^low^ population was first detected *NEUROG3* was enriched in the E^low^CD142^-^SUSD2^+^ subset ([Figure 6C](#fig6){ref-type="fig"}). Our results indicate that endocrine progenitors first appear in the GP2^-^CD142^-^SUSD2^-^ subset and next mature within the E^low^CD142^-^SUSD2^+^ subset. *INS* is first detected in the E^low^ CD142^-^SUSD2^+^ subset and later on in the E^low^CD142^-^SUSD2^-^ subset.

The E^low^CD142^-^SUSD2^+^ subset predominantly contains endocrine progenitors {#s2-6}
------------------------------------------------------------------------------

To assess the frequency of cells expressing endocrine progenitor (*NEUROG3, NEUROD1, NKX2-2*) and duct (*CFTR*) markers in the GP2^-^CD142^-^SUSD2^-^ and in the E^low^CD142^-^SUSD2^+^ subsets, we performed single cell RT-qPCR analyses at 9WD. The GP2^-^CD142^-^SUSD2^-^ subset was heterogeneous and composed of 78% *CFTR^+^NEUROG3 *cells, 16% *NEUROG3^+^* and 6% *CFTR^-^NEUROG3^-^* cells. Among the *NEUROG3^+^* , 47% were *NEUROD1^-^NKX2.2^-^*, 43% co-expressed *NEUROD1*, and 10% co-expressed *NEUROD1* and *NKX2.2*. Interestingly, 60% of *NEUROG3^+^* were *CFTR^+^* ([Figure 6D](#fig6){ref-type="fig"}). Conversely, only 2% of the E^low^CD142^-^SUSD2^+^ subset was *CFTR^+^NEUROG3^-^,* while 74% was *NEUROG3^+^* and 24% *CFTR^-^NEUROG3^-^. NEUROG3^+^* were essentially homogenous as 100% expressed *NEUROD1^+^* and 83% co-expressed *NKX2-2* as well ([Figure 6E](#fig6){ref-type="fig"}). Our findings demonstrate that the majority of the E^low^CD142^-^SUSD2^+^ subset is *NEUROG3^+^* co-expressing *NEUROD1* and *NKX2-2.*

Human pluripotent stem cells differentiation into pancreatic endocrine cells mimics human fetal endocrine cell development {#s2-7}
--------------------------------------------------------------------------------------------------------------------------

To determine if similar cell populations were present in pancreatic endocrine cells derived from three hPSCs (SA121 hESC, AD2.1 iPSC, AD3.1 iPSC), these cells were differentiated to the corresponding stage (stage 5) where significant endocrine induction occurs ([Figure 7A](#fig7){ref-type="fig"}). CD142 and ECAD characterized three distinct populations: ECAD^+^CD142^+^, ECAD^+^CD142^-^ and ECAD^low^CD142^-^ as it is the case in the human fetal pancreas (9.4WD) ([Figure 7B,C](#fig7){ref-type="fig"}). Similar to the human fetal pancreas, SUSD2^+^ cells were enriched in the ECAD^low^CD142^-^ population ([Figure 7B,C](#fig7){ref-type="fig"}). Moreover, *NEUROG3*, *NEUROD1* and *NKX2-2* were mainly expressed in the ECAD^low^CD142^-^SUSD2^+^ population as observed in the human fetal pancreas at 8.6WD ([Figures 6A,C](#fig6){ref-type="fig"} and [7D](#fig7){ref-type="fig"}). Finally, from stage 2--5 the temporal expression pattern of CD142 and ECAD was reminiscent of the ones occurring in the human fetal pancreas with a sharp decrease of CD142^+^SUSD2^-^ subsets (from 95 ± 2 of CD142^+^SUSD2^-^ at stage 2 to 23 ± 4 of CD142^+^SUSD2^-^ subset; p\<0.05) ([5D](#fig5){ref-type="fig"} and [7E](#fig7){ref-type="fig"}), as was also the case for SUSD2 expression ([Figures 5E](#fig5){ref-type="fig"} and [7F](#fig7){ref-type="fig"}) in the three hPSC lines. To conclude we demonstrate that pancreatic endocrine cells derived from human pluripotent stem cells appear to go through the same intermediate developmental stages as observed during in vivo development.10.7554/eLife.27564.018Figure 7.Expression of CD142, ECAD and SUSD2 in pancreatic endocrine cells derived from hPSCs.(**A**) Scheme of in vitro differentiation of hPSCs into endocrine pancreatic cells. (**B, C**) Expression of CD142, ECAD (gated on lived CD45^-^CD31^-^EPCAM^+^ cells for the human) and SUSD2 in CD142^+^, CD142^-^ and E^low^ population by flow cytometry in the human fetal pancreas at 9.4WD (in B) and in pancreatic endocrine cells derived from hPSCs (AD3.1 iPSC) at stage 5 (in C). (**D**) RT-qPCR on CD142^+^E-CAD^+^SUSD2^-^ (named CD142^+^), CD142^-^E-CAD^+^SUSD2^-^ (named CD142^-^), CD142^-^E-CAD^low^SUSD2^+^ (named E^low^SUSD2^+^), CD142^-^E-CAD^low^SUSD2^-^ (named E^low^SUSD2^-^) from hPSCs (AD3.1 iPSC) at stage five for *NEUROG3*, *NEUROD1* and *NKX2-2*). (**E**) Cell frequencies of CD142^+^SUSD2^-^ (in yellow) and CD142^-^SUSD2^-^ (in red) from hPSCs (SA121 hESC, AD2.1 iPSC, AD3.1 iPSC) from stage 2--5. (**F**) Cell frequencies of E^low^SUSD2^+^ and E^low^SUSD2^-^ from hPSCs (SA121 hESC, AD2.1 iPSC, AD3.1 iPSC) from stage 2--5. (**G**) Scheme representing human pancreatic differentiation across development using cell surface markers. (**B--F**) n = 3. \*p\<0.05, \*\*p\<0.001, \*\*\*p\<0.005, *t* test.**DOI:** [http://dx.doi.org/10.7554/eLife.27564.018](10.7554/eLife.27564.018)10.7554/eLife.27564.019Figure 7---figure supplement 1.Expression of CD142 and SUSD2 in the mesenchyme, the endothelial/hematopoietic and the epithelial compartments.Human fetal pancreas at 10.6WD was stained for CD45, CD31, EPCAM, CD142 and SUSD2. CD142 and SUSD2 expressions are displayed in the CD45^+^/CD31^+^ (in red), CD45^-^CD31^-^EPCAM^-^ (in green) and in CD45^-^CD31^-^EPCAM^+^ (in blue) populations on lived cells. n = 5.**DOI:** [http://dx.doi.org/10.7554/eLife.27564.019](10.7554/eLife.27564.019)

Discussion {#s3}
==========

In this study, we reconstruct human fetal pancreatic differentiation by combining a specific combination of cell surface markers. Although a large set of data is available concerning development in rodent models, there is only limited knowledge on human development. Importantly, while rodent and human pancreatic development share many similarities, they differ on several aspects ([@bib48]; [@bib36]). For example, the global shape and the way islet cells cluster are different between rodent and human pancreas ([@bib7]). Moreover, the expression pattern of major transcription factors crucial for proper pancreas development such as NEUROG3, NKX2-2 and PDX1 differ between rodent and human ([@bib57]; [@bib46]; [@bib27]; [@bib54]; [@bib38]; [@bib23]). As an example, NEUROG3 is expressed in two waves during rodent fetal pancreatic development ([@bib57]) while only a single-phase is observed in human ([@bib27]). It can be speculated that the number of differences between rodents and humans are under-estimated and more will be discovered by studying human pancreatic development. This knowledge will be essential to better design protocols to direct pluripotent stem cells towards functional insulin-producing pancreatic beta cells ([@bib39]; [@bib43]; [@bib45]).

Major progress has recently been made in the field of hPSC differentiation and a number of different cell types can be efficiently generated either in vivo following transplantation into immune-incompetent mice or in vitro under controlled conditions. However, the cells generated in vitro from hPSC do not seem fully differentiated and in some cases, display a fetal phenotype rather than an adult one. This is the case for hepatocytes ([@bib3]), cardiomyocytes ([@bib31]), neurons ([@bib41]) and pancreatic beta cells ([@bib26]). These partial successes could be in part due to the limited knowledge on human cell development. Here, we specifically designed new approaches to dissect in great detail pancreatic differentiation in human. We based our study on human fetal pancreases from 7 to 13WD. This developmental period corresponds to E12.5-E17 in the mouse when pancreatic progenitors first proliferate and next develop into differentiated cells ([@bib18]; [@bib28]). At 6-7WD, the human pancreatic epithelium is mainly composed of PDX1^+^NKX6-1^+^ pancreatic progenitors ([@bib11]; [@bib44]) while endocrine cells are extremely rare ([@bib42]; [@bib10]). During the following weeks, proliferating epithelial pancreatic progenitors differentiate into endocrine, acinar and duct cells ([@bib27]; [@bib8]).

The fetal pancreas is a compound organ composed of epithelial, mesenchymal, endothelial and hematopoietic cells. We excluded endothelial and hematopoietic cells using CD31 and CD45 antibodies and used the transmembrane glycoprotein EPCAM as a marker to segregate the fetal pancreatic epithelium from the mesenchyme. Previous data indicated that EPCAM is expressed during human fetal life (18-20WD) in the ductal pancreatic epithelium and in developing islet-like cells but also in the adult human pancreas in duct and islet cells ([@bib12]). Based on this previous report we demonstrated that EPCAM also marks the fetal pancreatic epithelium at earlier developmental stages, between 7 and 12WD. Moreover, we demonstrated that the EPCAM^+^ compartment contains PDX1^+^NKX6-1^+^ double-positive cells, a hallmark of pancreatic progenitors ([@bib27]; [@bib11]). Our data also indicate that 45% of the EPCAM^+^ compartment expresses lower levels of PDX1 and NKX6-1. It would be interesting to determine if these cells are upstream progenitors of EPCAM^+^PDX1^+^NKX6-1^+^ cells as recently suggested ([@bib1]). Then we further segregated the fetal pancreatic epithelium into four distinct populations using the cell surface markers GP2 and ECAD. GP2 is a glycoprotein that is highly enriched in the acinar cells of the adult pancreas ([@bib25]; [@bib58]). Limited knowledge is available on GP2 expression during pancreatic development. Very recently, using a model of pluripotent stem cells differentiation into pancreatic endocrine cells, GP2 was identified as a novel cell surface marker of human pancreatic progenitors ([@bib1]). Our ex vivo data further support this claim. First, we observed that at 7WD, nearly all pancreatic epithelial cells are GP2^+^. Moreover, as development proceeds, the frequency of GP2^+^ cells decreases. Finally, transcriptomic profiling performed at different developmental stages strongly suggests that the GP2^+^ population can differentiate into endocrine and exocrine cells. Collectively, these data indicate that in the early human fetal pancreas, GP2 is indeed a cell surface marker of a multipotent cell population. Although the GP2^+^ cell population is multipotent, it is not yet certain if the GP2^+^ population contains multipotent GP2^+^ progenitor that can differentiate into the three lineages (endocrine, acinar and ductal) or represent a mixture of GP2^+^ progenitors already committed to a specific lineage. This could be addressed by utilizing a single cell culture approach. However, our attempts so far to culture so few cells sorted from human fetal pancreas have failed. Discovering new and efficient culture conditions such as co-culture on feeder layers could alleviate this issue ([@bib55]).

In animal models, cell adhesion molecules have emerged as key regulators of embryonic morphogenesis and this topic has been extensively studied using pancreatic development as a model organ ([@bib50]). As an example, during mouse and chick development, Pdx1^+^Nkx6.1^+^ progenitors express high levels of ECAD. NEUROG3^+^ endocrine progenitors will develop from such pancreatic progenitors while lowering their ECAD level during their delamination from the ductal tree to develop into pancreatic endocrine cells ([@bib19]). Information remains scarcer on the regulation of ECAD levels during human development. Our results indicate that at 7WD, GP2^+^ pancreatic progenitors express ECAD at high levels. At 8.6WD, ECAD^low^ cells appear, their frequency increasing while development progresses. Interestingly, NEUROG3-expressing cells first appear at 8.4WD in the ECAD^+^ population and are found later on in the ECAD^low^ population. Whether it is linked to their delamination remains to be demonstrated. This step is followed (at 8.6WD) by the expression of endocrine markers such as *CHGA*, *NEUROD1* and *INS.* Of importance, endocrine cells expressed low but significant levels of ECAD. This perfectly fits with mouse data that indicate that during development ECAD function is necessary for proper aggregation of endocrine cells after delamination ([@bib13]). Taken together, our data demonstrate that ECAD levels are tightly regulated during specific steps of human pancreatic development.

We further refined specific pancreatic cell populations by using CD142 and SUSD2 found in our transcriptomic analysis as additional cell surface markers. CD142 has been proposed as a marker of pancreatic endodermal cells that also labels additional cell types ([@bib32]). SUSD2 was previously used as a marker to enrich *NEUROG3^+^* from hPSC derived pancreatic cells and the human fetal pancreas ([@bib33]). Here, with our set of markers we reconstructed human pancreatic cell differentiation ([Figure 7G](#fig7){ref-type="fig"}). The full combination of markers was required for this reconstruction as none of the markers was specific to the different subsets ([Figure 7---figure supplement 1](#fig7s1){ref-type="fig"}). Our data indicate that GP2^+^CD142^+^ pancreatic progenitors can either give rise to GP2^hi^CD142^+^ acinar cells or enter the endocrine pathway and express *NEUROG3* by turning off GP2 and CD142. Endocrine maturation further progresses by up-regulating SUSD2 and decreasing ECAD level ([Figure 7G](#fig7){ref-type="fig"}). The first *INS^ +^* cells were detected at 8.6WD in the E^low^ population as SUSD2^+^ and later on as SUSD2^-^. Recently, differences in gene expression and functionality were observed between fetal, neonatal and adult beta cells ([@bib26]; [@bib29]; [@bib6]). Moreover, heterogeneity between adult beta cells was also recently described ([@bib15]; [@bib2]). Whether *INS^ +^* cells positive for SUSD2 represent a first wave of beta cells that could be poly-hormonal remains to be tested. Moreover, comparative analyses between *INS^ +^* cells from E^low^SUSD2^+^ and E^low^SUSD2^-^ subsets will define the differences in their transcriptional factor networks.

FACS-based approaches have been used since the eighties in the hematopoietic field to dissect hematopoiesis ([@bib51]). However, it has rarely been used in the field of pancreatic development and even less frequently with human fetal pancreases. In the pancreas, the majority of the cell sorting approaches was performed by analyzing fluorescent signals from tagged proteins derived from transgenic mice ([@bib22]; [@bib35]). While highly informative, this strategy cannot be used to dissect human pancreatic development. Antibodies against cell surface markers were used in a limited number of studies on pancreas development and mainly in rodents. It was found that a combination of CD49f and CD133 antibodies can be used to enrich fraction in mouse pancreatic progenitors expressing *NEUROG3*-expressing cells with some data on human fetal pancreas. However, the enrichment in *NEUROG*3 on human fetal pancreas was limited using this combination of markers ([@bib53]). More recently, SUSD2 was used as a marker to enrich NEUROG3^+^ cells in hPSC -derived pancreatic cells and in the human fetal pancreas ([@bib33]). Our data confirm this point. However our single cell qPCR indicate that SUSD2 does not mark all, but only a subset of *NEUROG3^+^* that co-expressed *NEUROD1* and *NKX2-2*. Thus, by using a combination of antibodies against cell surface markers, we demonstrate that cell populations highly enriched in specific functions can be sorted from the human fetal pancreas at different stages of development, allowing the reconstruction of the differentiation program. Our model constitutes a key advancement in understanding human fetal pancreas development by mapping out the pattern of differentiation of the three main pancreatic lineages. We further refined our work for the endocrine pathway by describing for the first time, discrete stages of human pancreatic endocrine cell differentiation and showed that our development model also applies to the in vitro differentiation of hPSCs into pancreatic endocrine cells. To the best of our knowledge, this type of side-by-side comparison that demonstrates that in vitro hPSC differentiation mimics in vivo events has rarely been done.

In conclusion, we provide a novel way of approaching human pancreatic differentiation. Our work will be useful to fill the limited knowledge on human pancreas development. It should also pave the way for developing new cell therapies for diabetic patients.

Materials and methods {#s4}
=====================

Pancreatic dissection and cell suspension preparation {#s4-1}
-----------------------------------------------------

All experiments on human fetal pancreas were performed at INSERM Paris, France. Human fetal pancreases were isolated from surgical abortion done by suction aspiration between 7 to 13 weeks of development ([@bib10]; [@bib8]; [@bib47]) in compliance with the French bioethics legislation and the guidelines of our institution. Approval was obtained from Agence de Biomedecine, the French competent authority along with maternal written consent. Ages were determined on the basis of time since the last menstrual period and hand and foot morphology. Fetal pancreases were micro dissected with forceps under a binocular magnifying lens, rinsed with Hanks Balanced Salt Solution (HBSS) from Gibco to remove contaminating blood cells and gently disrupted using forceps. Afterwards, pancreases were incubated for 5 min in collagenase V (0.5 mg/ml) (Sigma Aldrich) in HBSS in the presence of calcium and magnesium. Cells were rinsed in HBSS and then incubated for 5 min in trypsin (0.05%) (Gibco). Finally, cells were rinsed in HBSS supplemented with 20% Fetal calf serum (from Eurobio). Pluripotent stem cells were washed with PBS without Ca2^+^ and Mg2^+^ (Invitrogen, FRANCE) and incubated with TrypLE select for 1--3 min.

Maintenance and differentiation of human pluripotent stem cell lines {#s4-2}
--------------------------------------------------------------------

A human ESC (SA121) ([@bib24]) obtained from Takara and two iPSC (SB Ad2.1 and SB3.1) ([@bib56]) obtained from the StemBANCC consortium were applied for this study. These cell lines had been confirmed to be pluripotent by evaluation of pluripotency marker expression, tri-lineage differentiation and karyotyping and tested negative for mycoplasma contamination. All three lines were cultured in mTeSR1 medium (StemCell Technologies) on hESC-qualified matrigel (Corning). Cells were passaged every 3--4 days or when confluent by dissociating to a single cell solution using TrypLE select (ThermoFisher). Single cells were seeded onto freshly coated Matrigel tissue culture flask in mTeSR1 containing of 5 uM Tiger (Rock inhibitor, Sigma-Aldrich) and medium was replenished daily. For differentiation of the hESC/hiPSC lines cells were dissociated to a single cell solution using TrypLE select and resuspended mTeSR1 with 5 uM Tiger. Cells were seeded at a concentration of 0.35 × 10^6^ cells/cm^2^ onto growth-factor reduced matrigel CellBIND surfaces (Corning). Cells were incubated for 24 hr before the start of the differentiation. Differentiation to the pancreatic lineage was conducted as described in a previously published protocol ([@bib43]) with the following modifications: CHIR99201 (Axon Medchem) was applied at 3 uM and 0.3 uM concentration for the first and second day, respectively of the definitive endoderm differentiation instead of MCX-928 used in the original protocol. MCDB131 medium (Life technologies) was used as basal medium throughout the differentiation instead of BLAR medium. Cells were not dissociated and incubated as clusters on air-liquid filters during stage 5; instead cells were kept in 2D cultures throughout the differentiation.

Flow cytometry {#s4-3}
--------------

Following dissociation, cells were incubated with antibodies for 20 min in FACS medium (HBSS +2% FCS), then rinsed in FACS medium and re-suspended in FACS medium with Propidium Iodide (1/4000) (Sigma Aldrich) or DAPI solution (0,1 ug/ml) (BD Biosciences) to label dead cells. For intra-cellular staining cells were fixed for 5 min in 3% PFA and then rinsed in DPBS from GIBCO. Then cells were permeabilized in DPBS +3% BSA +0.3% Triton and incubated with antibodies overnight at 4°C, rinsed and re-suspended in DPBS. For each antibody, optimal dilution was determined by titration. The following antibodies were used: anti CD45-PerCP/Cy5.5 (1/20, clone 2D1, Biolegend; RRID: [AB_2566351](https://scicrunch.org/resolver/AB_2566351)), anti CD31-PerCP/Cy5.5 (1/20, clone WM59, Biolegend; RRID: [AB_2566174](https://scicrunch.org/resolver/AB_2566174)), anti-EPCAM-Brillant violet 605 (1/20, clone 9C4, Biolegend; RRID: [AB_2562518](https://scicrunch.org/resolver/AB_2562518)), anti ECAD-PE-Cy7 (1/20, clone 67A4, Biolegend; RRID: [AB_2563096](https://scicrunch.org/resolver/AB_2563096)), anti-GP2-PE (1/5, clone 3G7H9, MBL; RRID: [AB_11160953](https://scicrunch.org/resolver/AB_11160953)), anti-SUSD2-VioBrightFITC (1/20, W5C5, Miltenyi Biotec; RRID: [AB_2653618](https://scicrunch.org/resolver/AB_2653618)), anti-CD142-VioBlue (1/20, clone HTF-1, Miltenyi Biotec; RRID: [AB_2655132](https://scicrunch.org/resolver/AB_2655132)), anti-PDX1-alexaFluor 488 (1/20, clone 658A5, BD Biosciences) and anti-NKX6-1-alexaFluor 647 (1/20, clone R11-560, BD Biosciences). An ARIA III (BD Bioscience) was used for cell sorting and a FACS LSRFortessa for analysis (BD Bioscience). Data were analyzed using FlowJo 10.2 software. Dead cells were excluded from analyses performed on lived cells. Lived cells referred to cells that did no incorporate the dead cell stain Propidium Iodide.

Immunohistochemistry {#s4-4}
--------------------

Human fetal pancreatic sections (4--5 μm thick) were prepared and processed as previously described ([@bib9]). The following primary antibodies were used anti-mouse EPCAM (1:500, clone VU1D9, Cell Signaling) and anti-rabbit PDX1 (1/1000) ([@bib16]). The secondary antibodies were anti-mouse Alexa Fluor 488 antibodies (1:400, Life Technologies) and anti-rabbit Alexa Fluor 594 antibodies (1:400, Jackson ImmunoResearch). The nuclei were stained using the Hoechst 33342 fluorescent stain (0.3 mg/ml, Invitrogen, France).

Bulk and single cells RT-qPCR {#s4-5}
-----------------------------

For human fetal pancreas, single to 100 cells were sorted in 9 μL of RT/pre-amp mix from the One-Step qRT-PCR Kit (Invitrogen, France). Pre-amplified (20 cycles) cDNA was obtained according to manufacturer's notice and was used for qPCR reaction. The pre-amplified cDNA was then used for qPCR using the TaqMan protocol. RT, pre-amplification and qPCR were performed using TaqMan primers from Applied Biosystems. The following TaqMan primers were used: *PPIA* (Hs04194521_s1), *HPRT1* (Hs99999909_m1), *PDX1* (Hs00236830_m1 and Hs00426216_m1), *NKX6-1* (Hs00232355_m1), *CEL* (Hs01068709_m1), *CELA2a* (Hs04194660_s1), *CELA3A* (Hs00371667_gH), *CTRC* (Hs00200713_m1), *SOX9* (Hs00165814_m1), *NEUROG3* (Hs01875204_s1), *CHGA* (Hs00900370_m1), *NEUROD1* (Hs01922995_s1), *INS* (Hs02741908), *NKX2-2* (Hs00159616_m1). RT-qPCR results are presented in arbitrary units (AU) relative to expression of the control gene *PPIA* (for human qPCR) and *HPRT* (for hPSC qPCRs). All qPCRs on the human fetal pancreas were assayed using *PPIA* while *HPRT* was used for the qPCR on hPSCs. QPCRs were run on QuantStudio from ThermoFischer and single cell qPCR were assayed on the Biomark from Fluidigm following manufacture's instructions.

For human pluripotent stem cell differentiation cells were sorted from three independent differentiations of the ADSB3.1 iPSC line. Cells were lysed in RP1 lysis buffer from the NucleoSpin RNA/Protein purification kit (Macherey-Nagel) and stored at −80°C until purification of RNA. RNAs were extracted using NucleoSpin RNA/protein purification kit. RNA was subsequently converted to cDNA using iScript cDNA synthesis kit (Biorad) according to manufactures instructions. RT-qPCR was performed on a MX3005P qPCR system (Agilent Genomics) using a fast-2-step protocol (first 95°C for 1 min, then 40 cycles of 95°C for 10 s, 60°C for 25 s). The following TagMan primers were used: *NEUROG3* (Hs01875204_s1), *NEUROD1* (Hs01922995_s1), *NKX2-2* (Hs00159616_m1), *bActin* (Hs01060665_g1) and *HPRT* (Hs99999909_m1).

Global transcriptomic analysis {#s4-6}
------------------------------

Total RNA was obtained from Trizol-preserved (Invitrogen, France) sorted cells by chloroform extraction, quantified and assessed for quality by Agilent-2100 Bioanalyzer (Agilent, Santa Clara, CA). cDNAs were prepared and amplified using Ovation Pico WTA System V2 kit (NuGEN Technologies, San Carlos, CA, USA) and hybridized onto GeneChip Human Gene 2.0 ST Array (Affymetrix,Santa Clara, CA, USA). Quality Control and normalization (RMA) were conducted using Bioconductor Project software (<https://www.bioconductor.org>), which provides log2 transformed expression values. Data were extracted from raw CEL files using a custom GeneChip library file (CDF file) provided by <http://brainarray.mbni.med.umich.edu/CustomCDF> ([@bib14]).

Transcriptomic statistical analysis {#s4-7}
-----------------------------------

Two-sample comparisons were made using two-tailed Student t-test. Transcripts for which any p-value was above 0.05 were filtered out, leaving 6444 transcripts for further analyses. We compared expression of these genes in each cell population using Gene Set Enrichment Analysis (GSEA) software and the 'Biological Process' database of the Gene Ontology Consortium ([@bib52]). Biological processes with FDR q-value \<0.05 were considered significant.

### Cut off to define the 'specific enriched genes':  {#s4-7-1}

Each population (GP2^hi^, GP2^+^, GP2^-^, E^low^ and M) was compared to the other populations using two-tailed Student t-test. Genes were considered as enriched in a specific population when over-expressed (p-value\<0,05 and Fold Change \> 2) in a population compared to any of the others. The list of the 'specific enriched genes' is displayed in [supplementary file 1b and c](#SD3-data){ref-type="supplementary-material"}.

### Expression pattern of the enriched fetal genes in the adult pancreas:  {#s4-7-2}

We use data from the single-cell RNA-seq ([@bib49]). The normalized data are available on ArrayExpress (<http://www.ebi.ac.uk/arrayexpress/> experiments/E-MTAB-5060). Next, we generated heatmaps displaying the expression of the fetal 'specific enriched genes' in the adult acinar, alpha, beta, epsilon, gamma and ductal cells.

Heatmaps were generated by the 'heatmap2' function from gplots R package (<https://cran.r-project.org/web/packages/gplots/>) on standardized log2 expression values, with Pearson correlation as the distance function.
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###### Gene Ontology list.

\(a\) List of gene sets and corresponding genes used in GSEA analysis displayed in [Figure 3B](#fig3){ref-type="fig"}. Gene sets were obtained from the gene ontology database. (b) List of differentially expressed genes specific to each population at 9WD. E^low^: in yellow, GP2^-^: in purple, GP2^+^: in red, M: white. Values are displayed in Log2. (c) List of differentially expressed genes specific to each population at 11WD. E^low^: in yellow, GP2^-^: in purple, GP2^+^: in red, M: white. Values are displayed in Log2.

**DOI:** [http://dx.doi.org/10.7554/eLife.27564.020](10.7554/eLife.27564.020)

Major datasets {#s7}
--------------

The following dataset was generated:

Ramond C,Glaser N,Berthault C,Ameri J,Kirkegaard JS,Hansson M,Honoré C,Semb H,Scharfmann R,2017,Expression data from cells sorted from human fetal pancreas,<https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE96697>,Publicly available at NCBIGene Expression Omnibus (accession no: GSE96697)

Methods supplementary information {#s24}
=================================

Determination of the developmental stage {#s25}
----------------------------------------

Weeks of development (WD) were determined based on the length and the anatomy of the foot and the hand. We also used the Human Embryo Resource website (<https://embryology.med.unsw.edu.au/embryology/index.php/Embryonic_Development>). Then, the precise age was calculated with the length of the foot and the following formula: Age = 4.11 X Foot Length + 5.60 ([@bib34]) from the Egyptian Journal of Forensic Sciences).

Replicates {#s26}
----------

All replicates in this study are biological replicates. The 'n' in the figure legends indicates the numbers of independent biological replicates at each developmental stage. Each flow cytometry plot displays the results from a single human fetal pancreas. An unpaired Student's t-test was performed on the FACS data of [Figures 2D](#fig2){ref-type="fig"}, [5D--E](#fig5){ref-type="fig"} and [7E](#fig7){ref-type="fig"}. Below is the number of independent pancreas analyzed:

-   Figure 1A: 9 pancreases at 9.7WD

-   Figure 1C-D: 3 pancreases at 9WD

-   Figure 2A: 4 pancreases at 9.4WD

-   Figure 2C: 2 pancreases at 7WD, 9 pancreases at 8.4WD, 4 pancreases at 9.4WD, 5 pancreases at 12WD

-   Figure 5B: 3 pancreases at 9.4WD

-   Figure 5C: 2 pancreases at 7WD, 3 pancreases at 8.4WD, 3 pancreases at 11.3WD.

-   Figure 7B: 3 pancreases at 9.4WD

-   Figure 7C: three independent FACS analyses assayed on AD3.1 cell line differentiated until stage 5 day 1.

-   Figure 7E-F: three independent FACS analysis assayed on three different hPSC lines differentiated from stage 2 to 5: SA121 hESC, AD2.1 iPSC, AD3.1 iPSC. Figures display the data from the three lines.

The variability between individual fetal pancreases at the same WD is displayed in [Figures 2D](#fig2){ref-type="fig"}, [5D--E](#fig5){ref-type="fig"} and [7E--F](#fig7){ref-type="fig"}. 

### qPCR {#s27}

All qPCR are from three independent experiments derived from the sorting of three independent fetal pancreases.

### Global transcriptomic analysis {#s28}

We performed a global transcriptomic analyses on three independent pancreases at 9WD and three at 11WD.

The following populations were sorted:

-   At 9WD: GP2^+^ (triplicate), GP2^-^ (triplicate), E^low^ (duplicate) and M (triplicate)

-   At 11WD: GP2^hi^ (triplicate), GP2^+^ (triplicate), GP2^-^ (duplicate), E^low^ (triplicate) and M (triplicate)

The third replicate for E^low^ population at 9WD and GP2^-^ population at 11WD were excluded due to the poor quality of the RNA.

10.7554/eLife.27564.023

Decision letter

Hanley

Neil A

Reviewing editor

University of Manchester

,

United Kingdom

In the interests of transparency, eLife includes the editorial decision letter and accompanying author responses. A lightly edited version of the letter sent to the authors after peer review is shown, indicating the most substantive concerns; minor comments are not usually included.

Thank you for submitting your article \"Reconstructing human pancreatic organogenesis by mapping specific cell populations during development\" for consideration by *eLife*. Your article has been favorably evaluated by Mark McCarthy (Senior Editor) and three reviewers, one of whom is a member of our Board of Reviewing Editors. The following individuals involved in review of your submission have agreed to reveal their identity: Susana Chuva de Sousa Lopes (Reviewer \#2); Timo Otonkoski (Reviewer \#3).

The reviewers have discussed the reviews with one another and the Reviewing Editor has drafted this decision to help you prepare a revised submission.

Summary:

The authors have undertaken a cellular deconstruction of how the human pancreas develops by studying the expression dynamics of several surface markers between 7 and 12 weeks of development. There is particular focus on the insulin-producing β cells. The evolution of these cell populations was very dynamic during the developmental stages studied, demonstrating that endocrine cells arise in the population that down-regulates both ECAD and GP2 expression. Further refinement of the characterization was achieved by including the cell surface marker SUSD2. Finally, human pluripotent stem cells undergoing pancreatic differentiation were analysed by the same parameters, demonstrating that in vitro development followed the same principles identified in vivo.

Essential revisions:

The three referee reports are included as all raise important points that should be addressed (and would improve the manuscript). The major request focuses on more detailed analysis and reporting of existing data (and not the acquisition of new \'wet lab\' data). While all individual points should to be addressed in a revised manuscript and / or the accompanying rebuttal letter, there are some common themes to the referee reports:

1\) There is a need to improve the detail of the computational and statistical analyses. There would be benefit from incorporating existing datasets on other pancreatic cell-types into some of the analyses (as highlighted by reviewer 2). This would then assist in commenting on other endocrine cell-types (as requested by reviewer 3) and examining other important genes (PAX4 is mentioned by reviewer 1).

2\) There is scope to include more information on specific genes, for instance underlying the GO terms, either as part of the figures or as additional supplementary tables.

3\) All the data should be made freely available for download.

4\) The Materials and methods need far more detail to enable others to follow the work.

*Reviewer \#1:*

Thank you very much for letting me review this manuscript. The major novelty is in the cellular deconstruction of how a human organ (the pancreas) develops. This has not been undertaken before and is challenging for a solid organ (e.g. compared to the haematopoietic system). The data have direct translational benefit for stem cell researchers. I make comments to try and improve the manuscript.

1\) [Figure 1](#fig1){ref-type="fig"}. The data imply that a considerable number, 45% if I interpret the data correctly in [Figure 1E](#fig1){ref-type="fig"}, of EpCAM+ cells either lack or (more likely) have lower levels of PDX1 and NKX6.1. These are then excluded from downstream analyses. The immunohistochemistry and text imply that all EpCAM+ cells possess PDX1, i.e. these cells are pancreatic progenitors. What do the authors think these cells EpCAM+ / low PDX1/low NKX6.1 cells are? How do these cells fit with the notion of NKX6.1 \'low\' cells as described by the authors in their recent Cell Reports paper, Ameri et al.? In that study on differentiating hPSCs, these cells were argued to be earlier stage pancreatic progenitors with higher levels of cell proliferation. Perhaps the authors could integrate their thoughts on this topic into the current manuscript?

2\) At several places in the manuscript, there is mention of very precise timing, e.g. \'7.4 WD\'. What does this mean? How was such accuracy determined over and above 7WD or 8WD? Moreover, the authors described triplicate experiments: are these biological replicates at this very precise time point? Or technical replicates from a single human embryonic pancreas. The manuscript would benefit on full detail regarding human tissue use, perhaps as a supplementary table.

3\) Computational analyses. A number of improvements should be made to allow others to gain maximum benefit from the data.a) For instance, in the subsection "GP2 and ECAD define 4 populations in the human fetal pancreatic epithelium that develop sequentially" (and elsewhere) (unless I missed it) it is not clear what cut-offs were applied to define particular genes as enriched. I don\'t think this detail was in the Materials and methods. b) The genes underlying all the GO terms should be listed, perhaps as a supplementary table as this would help the reader interpret the data. c) \'We correlated these signatures with RNAseq Single Cell data\'. How were these correlations undertaken? d) The heatmaps in [Figure 4](#fig4){ref-type="fig"} refer to very few genes. Why? And if selected, why were these particular genes chosen and (presumably) others overlooked?

4\) Subsection "Acinar and endocrine functions segregate within the GP2 and ECAD populations", end of first paragraph and elsewhere (e.g. subsection "CD142 and SUSD2 reveal heterogeneity within the GP2^-^ and E^low^ populations during development", last paragraph): I would encourage the authors to avoid \'data not shown\'. Either include the data or remove the interpretation.

5\) I did not follow the text in the last paragraph of the subsection "CD142 and SUSD2 reveal heterogeneity within the GP2^-^ and E^low^ populations during development" referring to [Figure 2---figure supplement 2A, B](#fig2s2){ref-type="fig"}. This figure supplement does not detail SUSD2 or CD142?

6\) The broad transcriptomics data are useful but at present only a limited number of key genes are discussed. Would it be possible to describe some additional key factors, some of which have been notoriously difficult to track down accurately in native human embryonic/fetal pancreas, such as PAX4? The precision with which the authors have picked apart human pancreatic differentiation should offer an opportunity to narrow down when PAX4 becomes expressed and in which precise cell-type.

7\) [Figure 6A-B](#fig6){ref-type="fig"}. In the subsection "Endocrine progenitors develop in the GP2^-^ CD142^-^ SUSD2^-^ subset and mature within the E^low^SUSD2^+^ subset" the authors describe two different cell populations in which insulin is expressed in the earlier fetal pancreas at 8.6WD: an E^low^/CD142^-^/SUSD2^+^ population but not in the E^low^/CD142^-^/SUSD2^-^ population; and then the converse in older fetal pancreas at 10-12WD, namely in the E^low^/CD142^-^/SUSD2^-^ population but now not in the E^low^/CD142^-^/SUSD2^+^ population. At least to me, this is surprising as β cell differentiation operates over a window, i.e. β-cells are serially differentiating over time. Morphologically, there are differences-at the earlier time point β-cells tend to be scattered whereas at the later time point β-cells are more clustered. Therefore, my question is whether the authors have unearthed two distinct populations of β-cells?

*Reviewer \#2:*

The authors have studied the expression dynamics of several surface markers in human pancreas from 7-12 weeks of development, mainly by FACS; and suggest an order of events during the differentiation of several lineages in the human pancreas.

1\) The authors used single cell transcriptomics data from Segerstolpe et al. to generate [Figure 3---figure supplement 1A, B](#fig3s1){ref-type="fig"}, but I don\'t understand what values were used to generate the heatmap. I assume they used RPKM values, but the legend goes from -1 to 1, so I am confused. I suggest that figure is replaced by heatmaps for the selected genes showing all individual cells instead of using averages (?) and using RPKM values.

2\) For robustness, the set of cells from Muraro et al., 2016, Cell Systems, 3:385 should also be included in two extra independent heatmaps in [Figure 3---figure supplement 1A, B](#fig3s1){ref-type="fig"}. The authors should also include not only acinar, ductal, α and β, but also the mesenchymal, δ, ε and pp cells.

3\) The authors should use more than one HKG to normalize the QPCR results, the probes used are stable they could use bactin, HPRT and PPIA instead of just one of those (they already have the 3 probes in house).

4\) The authors differentiate hPSCs into pancreas progenitors, but from the results it is unclear which of the 3 different lines mentioned were used and for what experiments. Can this be clarified in the Results and figures? Were the 3 lines used for the same experiments? And are the results comparable? In [Figure 7](#fig7){ref-type="fig"}: Could you specify what hPSCs were used for what experiments?

5\) Discussion: you mention that culture of pancreatic cells have failed: could you be more specific about the reason for failure (cells don\'t attach; cells die; which conditions have you tried? What are the culture periods tried, etc.)?

6\) The authors mention in the Discussion Ptf1, Cpa1 and cMyc as marking multipotent progenitors in mice. These genes were not analysed in the human data set. Were they expressed (and if yes, in what cells)? Could you include those genes in the heatmap in [Figure 4B](#fig4){ref-type="fig"}?

7\) I don\'t understand what the samples with \"statistical significance\" in all QPCR graphs were compared to? Could you clarify that in the figures?

8\) [Figure 2A](#fig2){ref-type="fig"}: the authors show the cells in the blue square stained with GP2 and ECAD. Could the authors also present the other 2 populations (in the two black squares) for the markers GP2 and ECAD? You should have that data acquired.

9\) [Figure 3A, C](#fig3){ref-type="fig"}: If the authors want to present PCA in 3D, they have to provide lines projecting each dot into the lower area. The plots as presented are 2D...

*Reviewer \#3:*

In this study Ramond et al. have aimed to understand the sequential development of epithelial cell populations in the human fetal pancreas, focusing particularly on the emergence of the insulin-producing β cells. For this purpose, they have identified cell surface markers that were used to sort the cell populations between developmental stages estimated to represent 7-12 weeks. They identify a CD45-CD31-EPCAM+ population that includes the pancreatic progenitors. This population was then found to contain 4 subpopulations based on the expression of GP2 and E-Cadherin. The evolution of these cell populations was very dynamic during the developmental stages studied, demonstrating that endocrine cells arise in the population that downregulates both ECAD and GP2 expression. Further refinement of the characterization was achieved by including the cell surface marker SUSD2. Finally, human pluripotent stem cells undergoing pancreatic differentiation were analysed by the same parameters, demonstrating that the in vitro development follows the same principles identified in vivo.

Overall, the study represents an impressive amount of flow cytometry analysis in human fetal pancreas, taking into account the scarcity of this research material. These results contribute to the understanding of human pancreatic development and provide surface markers that could be utilized to isolate bona fide pancreatic endocrine progenitors. The novelty of the study relies in the combined used of previously reported and novel surface marker to delimit the target cell population, both in human fetal pancreas samples and stem cell derived cells. However, the novelty is decreased by the recent report by the same investigators (Ameri et al., Cell Reports 2017) in which GP2 was characterized as a surface marker for pancreatic endocrine progenitors in the human fetal pancreas and hPSCs.

The value of the study would be increased by adding the following analyses:

1\) Out of all endocrine cells, the analysis focuses only on β cells. In which populations do the other major endocrine cell populations reside? It would be interesting to see at which stage and in which population within the GP2^-^ ECAD^low^ SUSD2^+^ are other endocrine cell hormones than insulin expressed: is the GCG^+^ population in SUSD2^+^ or SUSD2^-^? What is the distribution of hormone+ endocrine cells in the single cell samples (6D and 6E)? Are there polyhormonal cells, as is often seen in hPSC differentiation?

2\) In the fourth paragraph of the Discussion the authors describe the GP2^+^ cell population to represent the multipotent \"tip\" cells described in the mouse embryo to express PTF1a, Cpa1 and c-Myc. Are these markers expressed in the human GP2^+^ cells?

The quality of the presentation and the statistical analysis should be improved:

1\) Many of the figures are difficult to interpret. In general, it would be advisable to present as much as possible of the results as the quantitative summary of all experiments (as in [Figure 2D](#fig2){ref-type="fig"}), and also include statistical comparison of the changes.

2\) The immunofluorescent image in [Figure 1B](#fig1){ref-type="fig"} should be made larger and clearer.

3\) The methods in general are only superficially described and there are no detailed supplementary methods.

10.7554/eLife.27564.024

Author response

*Reviewer \#1:*

*\[...\] 1) [Figure 1](#fig1){ref-type="fig"}. The data imply that a considerable number, 45% if I interpret the data correctly in [Figure 1E](#fig1){ref-type="fig"}, of EpCAM+ cells either lack or (more likely) have lower levels of PDX1 and NKX6.1. These are then excluded from downstream analyses. The immunohistochemistry and text imply that all EpCAM+ cells possess PDX1, i.e. these cells are pancreatic progenitors. What do the authors think these cells EpCAM+ / low PDX1/low NKX6.1 cells are? How do these cells fit with the notion of NKX6.1 \'low\' cells as described by the authors in their recent Cell Reports paper, Ameri et al.? In that study on differentiating hPSCs, these cells were argued to be earlier stage pancreatic progenitors with higher levels of cell proliferation. Perhaps the authors could integrate their thoughts on this topic into the current manuscript?*

The reviewer interpretation is correct. On [Figure 1E](#fig1){ref-type="fig"}, 45% of the EPCAM+ cells express low levels of PDX1 and NKX6-1. In this context, it would really be interesting to compare the proliferative potential of EPCAM+ cells in relation to their NKX6-1 level. Indeed, defining cells that can be amplified from the human fetal pancreas is an important topic in the field. As suggested, we highlighted in the third paragraph of the Discussion section, the comparison with the Ameri et al. work of the new version of the manuscript.

*2) At several places in the manuscript, there is mention of very precise timing, e.g. \'7.4 WD\'. What does this mean? How was such accuracy determined over and above 7WD or 8WD?*

We determined the developmental age based on the length of the foot and the anatomy of the foot and the hand. With such information, the precise age was calculated using the formula from Manjunatha et al., 2012 (the Egyptian Journal of Forensic Sciences): Age = 4.11 X Foot Length + 5.60. We have now included this information in the Appendix subsection "Determination of the developmental stage".

*Moreover, the authors described triplicate experiments: are these biological replicates at this very precise time point? Or technical replicates from a single human embryonic pancreas. The manuscript would benefit on full detail regarding human tissue use, perhaps as a supplementary table.*

All experiments represent *biological* replicates. We now added in the Appendix subsection "Replicates" that all replicates in the study are biological replicates.

*3) Computational analyses. A number of improvements should be made to allow others to gain maximum benefit from the data.a) For instance, in the subsection "GP2 and ECAD define 4 populations in the human fetal pancreatic epithelium that develop sequentially" (and elsewhere) (unless I missed it) it is not clear what cut-offs were applied to define particular genes as enriched. I don\'t think this detail was in the Materials and methods.*

We now describe this point in the Materials and methods subsection "Transcriptomic statistical analysis": the cut-offs we applied to define "specifically enriched genes": "Each population (GP2^hi^, GP2^+^, GP2^-^, E^low^ and M) was compared to the other populations using two-tailed Student t-test. Genes were considered as enriched in a specific population when over-expressed (p-value \< 0,05 and Fold Change \> 2) in a population compared to any of the others. The list of the "specific enriched genes" is displayed in Table I and II."

*b) The genes underlying all the GO terms should be listed, perhaps as a supplementary table as this would help the reader interpret the data.*

We now added [Supplementary file 1A](#SD3-data){ref-type="supplementary-material"} to describe the genes underlying all the GO terms.

*c) \'We correlated these signatures with RNAseq Single Cell data\'. How were these correlations undertaken?*

[Supplementary file 1B and 1C](#SD3-data){ref-type="supplementary-material"} displayed the lists of genes specifically enriched in GP2^hi^ and E^low^ populations. We next wanted to determine their expression pattern in the different adult human pancreatic cell types. For this purpose, we searched for the expression of these enriched genes in the Segerstolpe et al. 2016 single cell RNAseq data and generated heatmaps representing expression levels of the fetal enriched genes in the different adult pancreatic cell subpopulations. This is now described in the subsection "Transcriptomic statistical analysis".

*d) The heatmaps in [Figure 4](#fig4){ref-type="fig"} refer to very few genes. Why? And if selected, why were these particular genes chosen and (presumably) others overlooked?*

For [Figure 4](#fig4){ref-type="fig"}, we *selected* a limited number of genes known to be linked, based on the scientific literature, to pancreatic acinar and endocrine cell development. The term "selected" is now added in the second paragraph of the subsection "Acinar and endocrine functions segregate within the GP2 and ECAD populations". We have now also added a new supplementary figure ([Figure 3---figure supplement 2](#fig3s2){ref-type="fig"}) based on gene ontology lists.

*4) Subsection "Acinar and endocrine functions segregate within the GP2 and ECAD populations", end of first paragraph and elsewhere (e.g. subsection "CD142 and SUSD2 reveal heterogeneity within the GP2^-^ and E^low^ populations during development", last paragraph): I would encourage the authors to avoid \'data not shown\'. Either include the data or remove the interpretation.*

In the previous version of the manuscript, the term "data not shown" was used twice. It concerned:

1\) the comparative analysis between the Segerstolpe et al. 2016 RNAseq and the list of the specific enriched genes in the E^low^ population at 9WD. We now deleted this information.

2\) The expression of SUSD2 and CD142 at 8.6WD. Data are now shown in [Figure 5---figure supplement 1](#fig5s1){ref-type="fig"}.

*5) I did not follow the text in the last paragraph of the subsection "CD142 and SUSD2 reveal heterogeneity within the GP2^-^ and E^low^ populations during development" referring to [Figure 2---figure supplement 2A, B](#fig2s2){ref-type="fig"}. This figure supplement does not detail SUSD2 or CD142?*

The reviewer is correct. [Figure 2---figure supplement 2A, B](#fig2s2){ref-type="fig"} detailed the decreased expression of ECAD in GP2^-^ population between 8.4 to 9.4WD. We now added [Figure 5---figure supplement 1](#fig5s1){ref-type="fig"} in the new version of the manuscript that displays CD142 and SUSD2 expression at 8.6WD. We also modified the text in the subsection "CD142 and SUSD2 reveal heterogeneity within the GP2^-^ and E^low^ populations during development".

*6) The broad transcriptomics data are useful but at present only a limited number of key genes are discussed. Would it be possible to describe some additional key factors, some of which have been notoriously difficult to track down accurately in native human embryonic/fetal pancreas, such as PAX4? The precision with which the authors have picked apart human pancreatic differentiation should offer an opportunity to narrow down when PAX4 becomes expressed and in which precise cell-type.*

In the new version of the manuscript, we now display two more heatmaps for the acinar and endocrine pathways based on the GSEA analysis in [Figure 3---figure supplement 2](#fig3s2){ref-type="fig"}.

Concerning PAX4: It is true that while the role of PAX4 in rodent β cell development has been demonstrated, its expression pattern and role in human remains unknown. We cannot exclude differences between rodent and human for PAX4 expression, as is the case for the transcription factor NKX2-2, a target of NEUROG3 in human (Jennings Diabetes 2013). From [Figure 4B](#fig4){ref-type="fig"}, we have learned that *PAX4* expression is enriched in the E^low^ population both at 9 and 11WD. This information is indicated in the second paragraph of the subsection "Acinar and endocrine functions segregate within the GP2 and ECAD populations". As a note for the reviewer, we have started to collect preliminary data that suggest that within the E^low^ population, PAX4 is first expressed by the E^low^SUSD2^+^ subset. In addition, in this population, PAX4 appears to be co-expressed with *NEUROG3*. We are also investigating if *INS* is also co-expressed with PAX4. As this set of information is preliminary at this stage, we decided not to include it in the new version of the manuscript.

*7) [Figure 6A-B](#fig6){ref-type="fig"}. In the subsection "Endocrine progenitors develop in the GP2^-^ CD142^-^ SUSD2^-^ subset and mature within the E^low^SUSD2^+^ subset" the authors describe two different cell populations in which insulin is expressed in the earlier fetal pancreas at 8.6WD: an E^low^/CD142^-^/SUSD2^+^ population but not in the E^low^/CD142^-^/SUSD2^-^ population; and then the converse in older fetal pancreas at 10-12WD, namely in the E^low^/CD142^-^/SUSD2^-^ population but now not in the E^low^/CD142^-^/SUSD2^+^ population. At least to me, this is surprising as β cell differentiation operates over a window, i.e. β-cells are serially differentiating over time. Morphologically, there are differences-at the earlier time point β-cells tend to be scattered whereas at the later time point β-cells are more clustered. Therefore, my question is whether the authors have unearthed two distinct populations of β-cells?*

This is a very interesting question. At this point, we do not have proof, but want to test the hypothesis that E^low^/CD142^-^/SUSD2^+^*INS^+^* cells could represent transient progenitors or pre-β cells. For this purpose, we are currently assaying the differences between E^low^/CD142^-^/SUSD2^+^*INS^+^* and E^low^/CD142^-^/SUSD2^-^*INS^+^* cells by single cell qPCR. A working hypothesis is that E^low^/CD142^-^/SUSD2^+^*INS^+^* would be poly-hormonal, which would not be the case for the E^low^/CD142^-^/SUSD2^-^*INS^+^* cells. Again, performing this type of experiment takes time due to the limitation in the number of fetal pancreases we have access to. We now discuss this point in the fifth paragraph of the Discussion.

*Reviewer \#2:*

*The authors have studied the expression dynamics of several surface markers in human pancreas from 7-12 weeks of development, mainly by FACS; and suggest an order of events during the differentiation of several lineages in the human pancreas.*

*1) The authors used single cell transcriptomics data from Segerstolpe et al. to generate [Figure 3---figure supplement 1A, B](#fig3s1){ref-type="fig"}, but I don\'t understand what values were used to generate the heatmap. I assume they used RPKM values, but the legend goes from -1 to 1, so I am confused. I suggest that figure is replaced by heatmaps for the selected genes showing all individual cells instead of using averages (?) and using RPKM values.*

As proposed by the reviewer we deleted the previous [Figure 3---figure supplement 1A-B](#fig3s1){ref-type="fig"} and replaced it by new heat maps figure entitled [Figure 3---figure supplement 3A-B](#fig3s3){ref-type="fig"}. Values are now presented in RPKM (log2), displaying all individual cells.

*2) For robustness, the set of cells from Muraro et al., 2016, Cell Systems, 3:385 should also be included in two extra independent heatmaps in [Figure 3---figure supplement 1A, B](#fig3s1){ref-type="fig"}.*

We agree it would be interesting to include the data from Muraro et al., 2016. However the cut off used to define specific cell types (Β cell for example) is not given in the Muraro et al. publication. It is thus difficult to draw a heat map similar to the one we generated from the Segerstolpe et al. publication.

*The authors should also include not only acinar, ductal, α and β, but also the mesenchymal, δ, ε and pp cells.*

We agree and we are now displaying acinar, α, β, δ, epsilon, γ and ductal cells in the new [Figure 3---figure supplement 3](#fig3s3){ref-type="fig"}.

*3) The authors should use more than one HKG to normalize the QPCR results, the probes used are stable they could use bactin, HPRT and PPIA instead of just one of those (they already have the 3 probes in house).*

All qPCRs on the human fetal pancreas were assayed using *PPIA*. We now added this point in the Materials and methods.

We have compared *bactin, HPRT* and *PPIA* as house-keeping genes in the fetal human pancreas. *Bactin* was not selected as a house-keeping gene for the human fetal pancreas because it is expressed at different levels in the different cell populations. The use of *HPRT* was not convenient for our experiments where we are limited in the quantity of cDNA we are using for each qPCR reaction as it is detected at later cycles than PPIA.

*4) The authors differentiate hPSCs into pancreas progenitors, but from the results it is unclear which of the 3 different lines mentioned were used and for what experiments. Can this be clarified in the Results and figures? Were the 3 lines used for the same experiments? And are the results comparable? In [Figure 7](#fig7){ref-type="fig"}: Could you specify what hPSCs were used for what experiments?*

For [Figure 7C and D](#fig7){ref-type="fig"}, we used AD3.1 iPSC. For [Figure 7E and F](#fig7){ref-type="fig"} we used 3 different lines: SA121 hESC, AD2.1 iPSC, AD3.1 iPSC. This information now appears in the legend of [Figure 7](#fig7){ref-type="fig"}, in the Results, and the Materials and methods subsection "Human pluripotent stem cells differentiation into pancreatic endocrine cells mimics human fetal endocrine cell development". Results were comparable from one line to the other as displayed in [Figure 7E-F](#fig7){ref-type="fig"} by the limited variability observed from one experiment to the other.

*5) Discussion: you mention that culture of pancreatic cells have failed: could you be more specific about the reason for failure (cells don\'t attach; cells die; which conditions have you tried? What are the culture periods tried, etc.)?*

We faced 3 main issues. First we have been and remain limited by the number of fetal pancreases we have access to. Second, the number of sorted cells when using combinations of antibodies is low (between 1,000 and 5,000 cells per fraction) and culturing such a limited number of cells is really challenging. Third, during the culture period, half of the sorted cells die (even with ROCK inhibitor). Thus, at the end of the culture period, the remaining cells are extremely difficult to analyse. We clearly need more time and experiments to solve the problems we encounter. A possibility could be to use a feeder layer such as 3T3-J2 cells as recently described (Trott et al., Stem Cell Reports 8:1675--1688, 2017) to amplify early progenitors. We started to design such a type of approach.

*6) The authors mention in the Discussion Ptf1, Cpa1 and cMyc as marking multipotent progenitors in mice. These genes were not analysed in the human data set. Were they expressed (and if yes, in what cells)? Could you include those genes in the heatmap in [Figure 4B](#fig4){ref-type="fig"}?*

According to our transcriptome data, *PTF1A, CPA1* and *MYC* are expressed in the human fetal pancreas and enriched in GP2^+^ compared to the E^low^ population. This information can be extracted from the GEO platform (GSE96697) where we uploaded our data. But we did not test them in qPCRs. Following comments from the three reviewers we removed this paragraph.

*7) I don\'t understand what the samples with \"statistical significance\" in all QPCR graphs were compared to? Could you clarify that in the figures?*

Thank you for pointing out this point. The comparisons are now directly highlighted on the figures. Please see [Figures 4](#fig4){ref-type="fig"}, [6](#fig6){ref-type="fig"} and 7.

*8) [Figure 2A](#fig2){ref-type="fig"}: the authors show the cells in the blue square stained with GP2 and ECAD. Could the authors also present the other 2 populations (in the two black squares) for the markers GP2 and ECAD? You should have that data acquired.*

We indeed had the data already acquired. Information on this topic now appears on [Figure 2---figure supplement 1](#fig2s1){ref-type="fig"}. The expression of GP2 and E-CADHERIN in CD45+/CD31+ is now presented in the red square and the expression of GP2 and E-CADHERIN in the CD45-CD31-EPCAM- in the green square.

*9) [Figure 3A, C](#fig3){ref-type="fig"}: If the authors want to present PCA in 3D, they have to provide lines projecting each dot into the lower area. The plots as presented are 2D.*

We agreed and now display the PCA in 2D into 3 parts in [Figure 3---figure supplement 1](#fig3s1){ref-type="fig"}.

*Reviewer \#3:*

*\[...\] The value of the study would be increased by adding the following analyses:*

*1) Out of all endocrine cells, the analysis focuses only on β cells. In which populations do the other major endocrine cell populations reside? It would be interesting to see at which stage and in which population within the GP2^-^ ECAD^low^ SUSD2^+^ are other endocrine cell hormones than insulin expressed: is the GCG^+^ population in SUSD2^+^ or SUSD2^-^? What is the distribution of hormone+ endocrine cells in the single cell samples (6D and 6E)? Are there polyhormonal cells, as is often seen in hPSC differentiation?*

Our data ([Figure 4B](#fig4){ref-type="fig"}) indicate that *INS, GCG* and *GHRL* are expressed in the E^low^ population. This is the case both at 9 and 11WD. As pointed by the reviewer, in our previous single cell analysis ([Figure 6D-E](#fig6){ref-type="fig"}), we did not include primers for hormones. We recently started to repeat the experiments looking at hormones following single cell qPCR. But, please keep into account that we remain limited by the scarcity of the fetal pancreases. The objective of the experiment is to further characterize the ECAD^low^ SUSD2^+^ and ECAD^low^ SUSD2^-^ subsets. We are for example asking whether poly-hormonal cells are detected. As a flavour, our first preliminary data indicate that ECAD^low^ SUSD2^-^ subset is highly enriched in *INS* mRNA when compared to ECAD^low^ SUSD2^+^ subset.

*2) In the fourth paragraph of the Discussion the authors describe the GP2^+^ cell population to represent the multipotent \"tip\" cells described in the mouse embryo to express PTF1a, Cpa1 and c-Myc. Are these markers expressed in the human GP2^+^ cells?*

According to our transcriptome data, *PTF1a*, *CPA1* and *cMYC* are expressed in the human fetal pancreas. And enriched in GP2^+^ compared to the E^low^ population. This information can be extracted from the GEO platform (GSE96697) where we uploaded our data. But we did not test them in qPCRs. Following comments from the three reviewers we removed this paragraph.

The quality of the presentation and the statistical analysis should be improved:

*1) Many of the figures are difficult to interpret. In general, it would be advisable to present as much as possible of the results as the quantitative summary of all experiments (as in [Figure 2D](#fig2){ref-type="fig"}), and also include statistical comparison of the changes.*

[Figure 2D](#fig2){ref-type="fig"}, [Figure 5D-E](#fig5){ref-type="fig"} and [Figure 7E-F](#fig7){ref-type="fig"} represent the quantitative summaries of the flow cytometry experiments with means ( ± SEM). We are now also providing the p values throughout the Results section.

*2) The immunofluorescent image in [Figure 1B](#fig1){ref-type="fig"} should be made larger and clearer.*

The previous image had been compressed and we are now providing a better quality image of [Figure 1B](#fig1){ref-type="fig"}.

*3) The methods in general are only superficially described and there are no detailed supplementary methods.*

We now modified the Materials and methods section and added an Appendix--- Methods supplementary information.

Specifically:

We added a paragraph to explain how we determined weeks of development (in Appendix---Methods supplementary information).

We recapitulated the number of biological replicates used in this study for each experiment (in Appendix---Methods supplementary information).

We reformatted the transcriptome part in the Materials and methods and detailed the cut off used for the transcriptome analysis.

We reformulated the way we compared our transcriptomic data with the single cell RNAseq from Segerstolpe et al. (in the Materials and methods).

We detailed the minor modifications of the protocol for the differentiation of the hPSC (in the Materials and methods).
